<DOC>
	<DOCNO>NCT00908180</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . Monoclonal antibody , alemtuzumab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect . PURPOSE : This phase II trial study side effect give carmustine together etoposide , cytarabine , melphalan , alemtuzumab follow donor stem cell transplant see well work treat patient relapsed refractory Hodgkin lymphoma .</brief_summary>
	<brief_title>Carmustine , Etoposide , Cytarabine , Melphalan , Alemtuzumab Followed Donor Stem Cell Transplant Treating Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To document toxicity feasibility reduced-intensity condition regimen comprise carmustine , etoposide , cytarabine , melphalan , alemtuzumab follow allogeneic hematopoietic stem cell transplantation patient primary refractory relapse Hodgkin lymphoma . - To document survival patient treat regimen . OUTLINE : This multicenter study . - Conditioning regimen : Patients receive BEAM chemotherapy comprise carmustine IV 2 hour day -6 , etoposide IV ≥ 1 hour day -5 -2 , cytarabine IV 15 minute twice daily day -5 -2 , melphalan IV day -1 . Patients also receive alemtuzumab IV day -5 -1 . - Allogeneic hematopoietic stem cell transplantation ( HSCT ) : Patients undergo allogeneic HSCT day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV ( orally tolerable ) begin day -1 continue day 60 , follow taper absence GVHD . - Donor lymphocyte infusion ( DLI ) : Patients mixed chimerism stable residual disease 6 month HSCT disease progression relapse time HSCT may receive DLI absence GVHD . After completion study treatment , patient follow periodically 3 year . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis Hodgkin lymphoma , meet 1 follow criterion : Refractory initial multiagent induction therapy achieve less complete response one line salvage chemotherapy In first relapse achieve less partial response one line salvage chemotherapy No progressive disease Must HLAmatched ( ≥ 9/10 ) sibling unrelated donor available PATIENT CHARACTERISTICS : WHO performance status 01 Creatinine clearance ≥ 50 mL/min Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN LVEF ≥ 40 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 23 month completion study treatment No HIV positivity No malignancy within past 5 year , except nonmelanoma skin cancer stage 0 ( situ ) cervical carcinoma No concurrent serious medical condition would preclude allograft No symptomatic respiratory compromise PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior highdose therapy allograft</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>